Novartis’ medicine Vijoice® (alpelisib) is intended to be used for the treatment of patients with PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million. The overgrowth disorders caused by PIK3CA mutations that fall under PROS includes: KTS, CLOVES syndrome, ILM, MCAP/M-CM, HME, HHML, FIL, FAVA, macrodactyly, muscular HH, FAO, CLAPO syndrome and epidermal nevus, benign lichenoid keratosis or seborrheic keratosis.
